J Korean Neurosurg Soc.  2023 Mar;66(2):133-143. 10.3340/jkns.2022.0091.

Investigating the Potential of Lipids for Use as Biomarkers for Glioblastoma via an Untargeted Lipidomics Approach

• Soylemez B
• Bulut Z
• Şahin-Bölükbaşı S

• KMID: 2539874
• DOI: http://doi.org/10.3340/jkns.2022.0091

Abstract

Objective
: The types and functions of lipids involved in glioblastoma (GB) are not well known. Lipidomics is a new field that examines cellular lipids on a large scale and novel aplication of lipidomics in the biomedical sciences have emerged. This study aimed to investigate the potential of blood lipids for use as biomarkers for the diagnosis of GB via untargated lipidomic approach. Gaining a deeper understanding of lipid metabolism in patients with GB can contribute to the early diagnosis with GB patiens and also development of novel and better therapeutic options.
Methods
: This study was performed using blood samples collected from 14 patients (eight females and six males) and 14 controls (eight females and six males). Lipids were extracted from blood samples and quantified using phosphorus assay. Lipid profiles of between patients with GB and controls were compared via an untargeted lipidomics approach using 6530 Accurate-Mass Q-TOF LC/MS mass spectrometer.
Results
: According to the results obtained using the untargeted lipidomics approach, differentially regulated lipid species, including fatty acid (FA), glycerolipid (GL), glycerophospholipid (PG), saccharolipid (SL), sphingolipid (SP), and sterol lipid (ST) were identified between in patients with GB and controls.
Conclusion
: Differentially regulated lipids were identified in patients with GB, and these lipid species were predicted as potential biomarkers for diagnosis of GB.

Keyword

Glioblastoma; Lipidomics; Electrospray Ionization mass spectrometry; Biomarkers; Cancer

Figure

• 

  Fig. 1. Principal component analysis (2d-PcA; A), partial least squares discriminant analysis (2d-PLS-dA; b), t-test (c), fold change (Fc) (d), and volcano (Vc) (e) plots of patients with glioblastoma and controls in positive ion mode.

• 

  Fig. 2. Orthogonal projections to latent structures discriminant analysis (OrthoPLSdA) diagram (A) and Orthogonal projections to latent structures discriminant analysis-variable importance projection (OrthoPLSdA-VIP) score (b) plot for lipid types different between patients with glioblastoma and controls (positive ion mode).

• 

  Fig. 3. Principal component analysis (2d-PcA; A), partial least squares discriminant analysis (2d-PLS-dA; b), t-test (c), fold change (Fc) (d), and volcano (Vc) (e) plots of patients with glioblastoma and controls in negative ion mode.

• 

  Fig. 4. Orthogonal projections to latent structures discriminant analysis (OrthoPLSdA) diagram (A) and Orthogonal projections to latent structures discriminant analysis-variable importance projection (OrthoPLSdA-VIP) score (b) plot for lipid types different between patients with glioblastoma and controls (negative ion mode).

Reference

References

1. Astarita G, Piomelli D. Towards a whole-body systems [multi-organ] lipidomics in Alzheimer’s disease. Prostaglandins Leukot Essent Fatty Acids. 85:197–203. 2011.

2. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 234:466–468. 1959.

3. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 5:e189. 2016.

4. Bilgin E, Duman BB, Altintas S, Cil T, Gezercan Y, Okten AI. Predictors of survival in Turkish patients with primary glioblastoma. Turk Neurosurg. 31:641–653. 2021.

5. Björkhem I, Lütjohann D, Diczfalusy U, Ståhle L, Ahlborg G, Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res. 39:1594–1600. 1998.

6. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 37:911–917. 1959.

7. Bretillon L, Sidén A, Wahlund LO, Lütjohann D, Minthon L, Crisby M, et al. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett. 293:87–90. 2000.

8. Del Boccio P, Pieragostino D, Di Ioia M, Petrucci F, Lugaresi A, De Luca G, et al. Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J Proteomics. 74:2826–2836. 2011.

9. Ejsing CS, Sampaio JL, Surendranath V, Duchoslav E, Ekroos K, Klemm RW, et al. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry. Proc Natl Acad Sci U S A. 106:2136–2141. 2009.

10. Guerrera IC, Astarita G, Jais JP, Sands D, Nowakowska A, Colas J, et al. A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients. PLoS One. 4:e7735. 2009.

11. Guo D, Bell EH, Chakravarti A. Lipid metabolism emerges as a promising target for malignant glioma therapy. CNS Oncol. 2:289–299. 2013.

12. Ha SJ, Showalter G, Cai S, Wang H, Liu WM, Cohen-Gadol AA, et al. Lipidomic analysis of glioblastoma multiforme using mass spectrometry. Anal Chem. 79:8423–8430. 2007.

13. Han X. Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer’s disease. Biochim Biophys Acta. 1801:774–783. 2010.

14. Holdhoff M, Yovino SG, Boadu O, Grossman SA. Blood-based biomarkers for malignant gliomas. J Neurooncol. 113:345–352. 2013.

15. Hu X, Matsumoto K, Jung RS, Weston TA, Heizer PJ, He C, et al. GPIHBP1 expression in gliomas promotes utilization of lipoprotein-derived nutrients. Elife. 8:e47178. 2019.

16. Jayaram S, Gupta MK, Polisetty RV, Cho WC, Sirdeshmukh R. Towards developing biomarkers for glioblastoma multiforme: a proteomics view. Expert Rev Proteomics. 11:621–639. 2014.

17. Jia L, Wang C, Zhao S, Lu X, Xu G. Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 860:134–140. 2007.

18. Kinsey GR, Blum JL, Covington MD, Cummings BS, McHowat J, Schnellmann RG. Decreased iPLA2gamma expression induces lipid peroxidation and cell death and sensitizes cells to oxidant-induced apoptosis. J Lipid Res. 49:1477–1487. 2008.

19. Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, et al. Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol Cancer Ther. 10:427–436. 2011.

20. LIPID MAPS^®. LIPID gateway, lipidomics. Available at : http://www.lipidmaps.org/.

21. MetaboAnalyst. MetaboAnalyst - statistical, functional and integrative analysis of metabolomics data. Available at : https://www.metaboanalyst.ca/.

22. Min HK, Lim S, Chung BC, Moon MH. Shotgun lipidomics for candidate biomarkers of urinary phospholipids in prostate cancer. Anal Bioanal Chem. 399:823–830. 2011.

23. Muro E, Atilla-Gokcumen GE, Eggert US. Lipids in cell biology: how can we understand them better? Mol Biol Cell. 25:1819–1823. 2014.

24. Navas-Iglesias N, Carrasco-Pancorbo A, Cuadros-Rodríguez L. From lipids analysis towards lipidomics, a new challenge for the analytical chemistry of the 21st century. Part II: analytical lipidomics. Trends Anal Chem. 28:393–403. 2009.

25. Ollero M, Astarita G, Guerrera IC, Sermet-Gaudelus I, Trudel S, Piomelli D, et al. Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients. J Lipid Res. 52:1011–1022. 2011.

26. Peterson B, Stovall K, Monian P, Franklin JL, Cummings BS. Alterations in phospholipid and fatty acid lipid profiles in primary neocortical cells during oxidant-induced cell injury. Chem Biol Interact. 174:163–176. 2008.

27. Pinto RC, Trygg J, Gottfries J. Advantages of orthogonal inspection in chemometrics. J Chemom. 26:231–235. 2012.

28. Sabbagh MN, Sandhu S, Kolody H, Lahti T, Silverberg NB, Sparks DL. Studies on the effect of the apolipoprotein E genotype on the lipid profile in Alzheimer’s disease. Curr Alzheimer Res. 3:157–160. 2006.

29. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 279:2610–2623. 2012.

30. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, et al. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res. 7:4266–4277. 2008.

31. Shukla G, Alexander GS, Bakas S, Nikam R, Talekar K, Palmer JD, et al. Advanced magnetic resonance imaging in glioblastoma: a review. Chin Clin Oncol. 6:40. 2017.

32. Taguchi R, Hayakawa J, Takeuchi Y, Ishida M. Two-dimensional analysis of phospholipids by capillary liquid chromatography/electrospray ionization mass spectrometry. J Mass Spectrom. 35:953–966. 2000.

33. Taïb B, Aboussalah AM, Moniruzzaman M, Chen S, Haughey NJ, Kim SF, et al. Lipid accumulation and oxidation in glioblastoma multiforme. Sci Rep. 9:19593. 2019.

34. Touboul D, Gaudin M. Lipidomics of Alzheimer’s disease. Bioanalysis. 6:541–561. 2014.

35. Tugnoli V, Tosi MR, Tinti A, Trinchero A, Bottura G, Fini G. Characterization of lipids from human brain tissues by multinuclear magnetic resonance spectroscopy. Biopolymers. 62:297–306. 2001.

36. Vaz FM, Pras-Raves M, Bootsma AH, van Kampen AH. Principles and practice of lipidomics. J Inherit Metab Dis. 38:41–52. 2015.

37. Wood PL. Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology. 39:24–33. 2014.

38. Yang K, Rich JN. A delicate initiation: lipolysis of lipid droplets fuels glioblastoma. Mol Cell. 81:2686–2687. 2021.

39. Zhang L, Peterson BL, Cummings BS. The effect of inhibition of Ca2+- independent phospholipase A2 on chemotherapeutic-induced death and phospholipid profiles in renal cells. Biochem Pharmacol. 70:1697–1706. 2005.

40. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol. 141:1115–1124. 1992.

41. Zhang Y, Wang Y, Guo S, Guo Y, Liu H, Li Z. Ammonia-treated N-(1-naphthyl) ethylenediamine dihydrochloride as a novel matrix for rapid quantitative and qualitative determination of serum free fatty acids by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry. Anal Chim Acta. 794:82–89. 2013.

42. Zhao YY, Cheng XL, Lin RC. Lipidomics applications for discovering biomarkers of diseases in clinical chemistry. Int Rev Cell Mol Biol. 313:1–26. 2014.

43. Zhou X, Mao J, Ai J, Deng Y, Roth MR, Pound C, et al. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS One. 7:e48889. 2012.

44. Zhou X, Mao J, He Z, Henegar J. Lipidomics in identifying lipid biomarkers of prostate cancer. FASEB J. 24(S1):354.6. 2010.